sur PolyPeptide Group
Samsung Biologics' Tender Offer for PolyPeptide: Interim Results Released
Samsung Biologics, via its subsidiary Samsung Peptide, announced the interim results of its public tender offer for PolyPeptide Group's shares. The offer concluded on October 12, 2026. Samsung Peptide now holds 87.92% of PolyPeptide's shares, with 87.59% tendered during the offer.
The offer's conditions regarding minimum acceptance and absence of adverse effects were met. Samsung Peptide plans a squeeze-out of remaining shareholders and seeks delisting from SIX Swiss Exchange. The additional acceptance period runs from October 19 to 30, 2026.
Regulatory approval is pending. Completion is expected by late 2026 or early 2027, with the settlement delayed as specified in the offer documentation. An extraordinary general meeting is scheduled for October 26 to address certain conditions.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de PolyPeptide Group